MXPA03009720A - USO DE ANTAGONISTAS DEL RECEPTOR DE NK-1 PARA TRATAMIENTO O PREVENCIoN DE HIPERPLASIA PROSTATICA BENIGNA. - Google Patents
USO DE ANTAGONISTAS DEL RECEPTOR DE NK-1 PARA TRATAMIENTO O PREVENCIoN DE HIPERPLASIA PROSTATICA BENIGNA.Info
- Publication number
- MXPA03009720A MXPA03009720A MXPA03009720A MXPA03009720A MXPA03009720A MX PA03009720 A MXPA03009720 A MX PA03009720A MX PA03009720 A MXPA03009720 A MX PA03009720A MX PA03009720 A MXPA03009720 A MX PA03009720A MX PA03009720 A MXPA03009720 A MX PA03009720A
- Authority
- MX
- Mexico
- Prior art keywords
- receptor antagonists
- benign prostatic
- prostatic hyperplasia
- antagonists against
- against benign
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01109853 | 2001-04-23 | ||
PCT/EP2002/001085 WO2002085458A2 (en) | 2001-04-23 | 2002-02-02 | Use of nk-1 receptor antagonists against benign prostatic hyperplasia |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA03009720A true MXPA03009720A (es) | 2004-01-29 |
Family
ID=8177209
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA03009720A MXPA03009720A (es) | 2001-04-23 | 2002-02-02 | USO DE ANTAGONISTAS DEL RECEPTOR DE NK-1 PARA TRATAMIENTO O PREVENCIoN DE HIPERPLASIA PROSTATICA BENIGNA. |
Country Status (17)
Country | Link |
---|---|
US (1) | US20030004157A1 (es) |
EP (1) | EP1385577B1 (es) |
JP (1) | JP4146730B2 (es) |
KR (1) | KR100599134B1 (es) |
CN (1) | CN100398106C (es) |
AR (1) | AR035935A1 (es) |
AT (1) | ATE323531T1 (es) |
AU (1) | AU2002250876B2 (es) |
BR (1) | BR0209151A (es) |
CA (1) | CA2444395C (es) |
DE (1) | DE60210760T2 (es) |
DK (1) | DK1385577T3 (es) |
ES (1) | ES2261657T3 (es) |
MX (1) | MXPA03009720A (es) |
PT (1) | PT1385577E (es) |
WO (1) | WO2002085458A2 (es) |
ZA (1) | ZA200308110B (es) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002089802A2 (en) * | 2001-05-08 | 2002-11-14 | Schering Corporation | Use of neurokinin receptor antagonists to treat androgen-dependent diseases |
US6849624B2 (en) | 2001-07-31 | 2005-02-01 | Hoffmann-La Roche Inc. | Aromatic and heteroaromatic substituted amides |
NZ541243A (en) * | 2003-01-31 | 2008-04-30 | Hoffmann La Roche | New crystalline modification of 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(1,1-dioxo-1lambda6-thiomorpholin-4-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide |
JP4490421B2 (ja) * | 2003-07-03 | 2010-06-23 | エフ.ホフマン−ラ ロシュ アーゲー | 統合失調症を処置するデュアルnk1/nk3アンタゴニスト |
ES2246687B2 (es) * | 2004-02-11 | 2006-11-16 | Miguel Muñoz Saez | Utilizacion de antagonistas no peptidicos de receptores nk1 para la produccion de apoptosis en celulas tumorales. |
JP4580426B2 (ja) | 2004-07-06 | 2010-11-10 | エフ.ホフマン−ラ ロシュ アーゲー | Nk−1受容体拮抗薬の合成において中間体として使用されるカルボキサミド誘導体の製造方法 |
US20060030600A1 (en) * | 2004-08-06 | 2006-02-09 | Patrick Schnider | Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia |
EP1855655A2 (en) | 2005-02-25 | 2007-11-21 | F. Hoffmann-Roche AG | Tablets with improved drug substance dispersibility |
SI2395002T1 (sl) | 2005-11-08 | 2014-10-30 | Vertex Pharmaceuticals Incorporated | Farmacevtski sestavek, vsebujoč heterociklični modulator prenašalcev z ATP-vezavno kaseto |
US7671221B2 (en) | 2005-12-28 | 2010-03-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
US7754739B2 (en) | 2007-05-09 | 2010-07-13 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
WO2008090114A1 (en) | 2007-01-24 | 2008-07-31 | Glaxo Group Limited | Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-) |
JP5497633B2 (ja) | 2007-05-09 | 2014-05-21 | バーテックス ファーマシューティカルズ インコーポレイテッド | Cftrのモジュレーター |
SI2225230T1 (sl) | 2007-12-07 | 2017-03-31 | Vertex Pharmaceuticals Incorporated | Trdne oblike 3-(6-(1-2,2-difluorobenzo(d)(1,3)dioxol-5-il)ciklopropan- karboksamido)-3-metilpiridin-2-il) benzojske kisline |
PL2639223T3 (pl) | 2007-12-07 | 2017-09-29 | Vertex Pharmaceuticals Incorporated | Sposób wytwarzania kwasów cykloalkilokarboksyamido-pirydyno-benzoesowych |
CA2931134C (en) | 2008-02-28 | 2019-07-30 | Vertex Pharmaceuticals Incorporated | Heteroaryl derivatives as cftr modulators |
GB0808747D0 (en) | 2008-05-14 | 2008-06-18 | Glaxo Wellcome Mfg Pte Ltd | Novel compounds |
WO2010106988A1 (ja) | 2009-03-17 | 2010-09-23 | 第一三共株式会社 | アミド誘導体 |
WO2010119347A1 (en) * | 2009-04-14 | 2010-10-21 | Helsinn Healthcare S.A. | Netupitant for use in treating bladder dysfunction |
EP2493299A4 (en) * | 2009-10-29 | 2013-04-17 | Merck Sharp & Dohme | TERTIARY AMIDOREXIN RECEPTOR ANTAGONISTS |
JP2013523833A (ja) | 2010-04-07 | 2013-06-17 | バーテックス ファーマシューティカルズ インコーポレイテッド | 3−(6−(1−(2,2−ジフルオロベンゾ[d][1,3]ジオキソール−5−イル)シクロプロパンカルボキサミド)−3−メチルピリジン−2−イル)安息香酸の医薬組成物およびその投与 |
EP3067349B1 (en) | 2013-11-08 | 2018-02-28 | Kissei Pharmaceutical Co., Ltd. | Carboxymethyl piperidine derivative |
RU2016122882A (ru) | 2013-11-12 | 2017-12-19 | Вертекс Фармасьютикалз Инкорпорейтед | Способ получения фармацевтических композиций для лечения опосредованных cftr заболеваний |
TWI649307B (zh) | 2014-05-07 | 2019-02-01 | 日商橘生藥品工業股份有限公司 | Cyclohexylpyridine derivative |
RU2691136C2 (ru) | 2014-11-18 | 2019-06-11 | Вертекс Фармасьютикалз Инкорпорейтед | Способ проведения высокопроизводительной тестовой высокоэффективной жидкостной хроматографии |
EP3746077A4 (en) * | 2018-02-02 | 2021-10-27 | Eustralis Pharmaceuticals Limited (Trading as Pressura Neuro) | PARENTERAL FORMULATIONS AND USES THEREOF |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6175013B1 (en) * | 1994-06-10 | 2001-01-16 | Eli Lilly And Company | Imidazolinyl tachykinin receptor antagonists |
FR2729951B1 (fr) * | 1995-01-30 | 1997-04-18 | Sanofi Sa | Nouveaux composes heterocycliques, procede pour leur preparation et compositions pharmaceutiques en contenant |
CN1272842A (zh) * | 1997-08-06 | 2000-11-08 | 伊莱利利公司 | 作为速激肽受体拮抗剂的2-酰氨基丙胺类化合物 |
IL134155A0 (en) * | 1997-08-06 | 2001-04-30 | Lilly Co Eli | 2-acylaminopropanamines as tachykinin receptor antagonists |
JPH11322748A (ja) * | 1998-03-19 | 1999-11-24 | Takeda Chem Ind Ltd | 複素環化合物、その製造法および用途 |
EP1035115B1 (en) * | 1999-02-24 | 2004-09-29 | F. Hoffmann-La Roche Ag | 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists |
AU3735000A (en) * | 1999-05-05 | 2000-11-21 | Warner-Lambert Company | Modulation of substance p by gaba analogs and methods relating thereto |
WO2002006236A1 (en) * | 2000-07-14 | 2002-01-24 | F. Hoffmann-La Roche Ag | N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives |
US6849624B2 (en) * | 2001-07-31 | 2005-02-01 | Hoffmann-La Roche Inc. | Aromatic and heteroaromatic substituted amides |
-
2002
- 2002-02-02 CA CA2444395A patent/CA2444395C/en not_active Expired - Lifetime
- 2002-02-02 DE DE60210760T patent/DE60210760T2/de not_active Expired - Lifetime
- 2002-02-02 CN CNB028087305A patent/CN100398106C/zh not_active Expired - Lifetime
- 2002-02-02 ES ES02719751T patent/ES2261657T3/es not_active Expired - Lifetime
- 2002-02-02 AT AT02719751T patent/ATE323531T1/de active
- 2002-02-02 WO PCT/EP2002/001085 patent/WO2002085458A2/en active IP Right Grant
- 2002-02-02 BR BR0209151-8A patent/BR0209151A/pt not_active Application Discontinuation
- 2002-02-02 EP EP02719751A patent/EP1385577B1/en not_active Expired - Lifetime
- 2002-02-02 PT PT02719751T patent/PT1385577E/pt unknown
- 2002-02-02 JP JP2002583031A patent/JP4146730B2/ja not_active Expired - Lifetime
- 2002-02-02 DK DK02719751T patent/DK1385577T3/da active
- 2002-02-02 KR KR1020037013798A patent/KR100599134B1/ko active IP Right Grant
- 2002-02-02 AU AU2002250876A patent/AU2002250876B2/en not_active Expired
- 2002-02-02 MX MXPA03009720A patent/MXPA03009720A/es active IP Right Grant
- 2002-02-07 AR ARP020100393A patent/AR035935A1/es unknown
- 2002-02-08 US US10/071,570 patent/US20030004157A1/en not_active Abandoned
-
2003
- 2003-10-17 ZA ZA2003/08110A patent/ZA200308110B/en unknown
Also Published As
Publication number | Publication date |
---|---|
BR0209151A (pt) | 2004-07-13 |
DE60210760D1 (de) | 2006-05-24 |
CN1503684A (zh) | 2004-06-09 |
WO2002085458A3 (en) | 2003-10-30 |
CA2444395A1 (en) | 2002-10-31 |
PT1385577E (pt) | 2006-08-31 |
ES2261657T3 (es) | 2006-11-16 |
AU2002250876B2 (en) | 2005-03-03 |
EP1385577A2 (en) | 2004-02-04 |
CN100398106C (zh) | 2008-07-02 |
KR100599134B1 (ko) | 2006-07-12 |
AR035935A1 (es) | 2004-07-28 |
WO2002085458A2 (en) | 2002-10-31 |
KR20040007503A (ko) | 2004-01-24 |
EP1385577B1 (en) | 2006-04-19 |
DE60210760T2 (de) | 2006-11-23 |
ATE323531T1 (de) | 2006-05-15 |
US20030004157A1 (en) | 2003-01-02 |
CA2444395C (en) | 2010-12-21 |
JP4146730B2 (ja) | 2008-09-10 |
DK1385577T3 (da) | 2006-08-21 |
JP2004529931A (ja) | 2004-09-30 |
ZA200308110B (en) | 2005-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA03009720A (es) | USO DE ANTAGONISTAS DEL RECEPTOR DE NK-1 PARA TRATAMIENTO O PREVENCIoN DE HIPERPLASIA PROSTATICA BENIGNA. | |
MXPA03006121A (es) | Terapia de combinacion usando inhibidores del receptor tirosin-cinasa e inhibidores de la angiogenesis. | |
ZA200401214B (en) | Synthesis of poly-alpha olefin and use thereof. | |
ITMI20002076A0 (it) | Procedimento ed apparecchiatura per il controllo della miscelazione di bevande. | |
IL169685A0 (en) | Treatment of benign prostatic hyperplasia using energolytic agents | |
MXPA03000738A (es) | Antagonistas de grelina. | |
PL363907A1 (en) | Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain. | |
HK1078266A1 (en) | Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and the use of the same | |
IL158701A0 (en) | Novel use of nk3 receptor antagonist | |
EP1359915A4 (en) | UROTENSIN-II RECEPTOR ANTAGONISTS | |
AU8177801A (en) | 1,4-diazepan-2,5-dione derivatives and their use as nk-1 receptor antagonists | |
MXPA03003892A (es) | Antagonistas del receptor bombesin. | |
ZA991315B (en) | Novel substituted pyridino arylpiperazines useful in the treatment of benign prostatic hyperplasia. | |
ZA200108038B (en) | Prophylactic use of n-methyl-d-asparrate (NMDA) antagonists. | |
WO2002062323A3 (en) | Use of mglur5 antagonists for the treatment of pruritic conditions | |
MXPA03004414A (es) | Natagonistas del receptor bombesin. | |
ZA200403530B (en) | Chemokine receptor antagonists and methods of use thereof. | |
HK1031872A1 (en) | Phtalimido arylpiperazines as alpha 1a receptor antagonists useful in the treatment of benign prostatic hyperplasia. | |
EP1372639A4 (en) | TREATMENT AGENT FOR BLADDER IRRITATION SYMPTOMS ACCOMPANIED WITH BENIGN PROSTATIC HYPERPLASIA | |
AU2001268442A1 (en) | Identification of cdnas associated with benign prostatic hyperplasia | |
ZA200401146B (en) | Agonists and antagonists of 5HT3-like receptor of invertebrates as pesticides. | |
DK1056720T3 (da) | Phtalimido-arylpiperaziner som alfa-1A-receptorantagonister, der er nyttige til behandling af godartet prostatahyperplasi | |
MXPA03004249A (es) | Nuevos usos de combinaciones selectivas antagonistas del receptor de dopamina d2 y agonistas del receptor de 5-ht1a. | |
AU2002348270A8 (en) | Fire hydrant lock | |
GB2382281B (en) | Authentication of network users |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |